Lennard YW Lee: We are now one of the leading cancer research infrastructure for personalised cancer vaccine trials
Lennard YW Lee,
“Feeling proud of my colleagues. Across the UK, on every radio station, new outlet and newspaper, there’s great news coming from my colleagues and the cancer community. “Personalised cancer vaccine trials”.
What’s the background to this?
- In recent years, our researchers have been really good at delivering vaccine research.
- mRNA technology means that it is now possible to make vaccines against the very abnormalities that cause cancer.
- You can prime the immune system to start to search and destroy cancer, hopefully stop it coming back.
- Trials are now up and running around the country. Trials made possible by amazing work by our clinical researchers like Christian Ottensmeier, Robert Jones, Mark Linch, Siow-Ming Lee, Heather Shaw, Will Ince, David James Pinato, Tom Powles, Stefan Symeonides, and many others.
There is now so many people pushing a UK cancer vaccine advance, and we are now one, if not the leading cancer research infrastructure for this technology. .
It was nice that the work by Birmingham, and Victoria Kunene was highlighted. The trust has done a fantastic turn around in recent years. I was trained at that cancer centre. Brilliant work to bring through the BioNtech studies into the centre.
If you want to hear more by the bulletin, do consider subscribing on LinkedIn.
We must also acknowledge the simply incredible work by the NHSE Team on their superb launchpad- Gillian Rosenberg, Nicola Chapman-Hart, Max S. Patrick, Benjamin Moxley-Wyles, Sarrah Tayabali and Peter Johnson.
And their supporting trials unit Victoria Goss and Nicole Keyworth. And NIHR VIP leads Maria Koufali and Sarah Danson. .
The vision is that in future, drugs can be made personalised for you, which will hopefully be more effective, safer and potentially given as easily as your other vaccines. Definitely good news on the horizon.”
Source: Lennard YW Lee/LinkedIn